JP2020526583A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020526583A5 JP2020526583A5 JP2020521496A JP2020521496A JP2020526583A5 JP 2020526583 A5 JP2020526583 A5 JP 2020526583A5 JP 2020521496 A JP2020521496 A JP 2020521496A JP 2020521496 A JP2020521496 A JP 2020521496A JP 2020526583 A5 JP2020526583 A5 JP 2020526583A5
- Authority
- JP
- Japan
- Prior art keywords
- aqueous
- lactobacillus
- dry powder
- bacterial suspension
- storage medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000843 powder Substances 0.000 claims description 38
- 230000001580 bacterial effect Effects 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 26
- 239000000654 additive Substances 0.000 claims description 25
- 239000000725 suspension Substances 0.000 claims description 23
- 241000186660 Lactobacillus Species 0.000 claims description 22
- 230000000996 additive effect Effects 0.000 claims description 20
- 229940039696 lactobacillus Drugs 0.000 claims description 12
- 239000008188 pellet Substances 0.000 claims description 12
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 10
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 10
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 10
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 10
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 10
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 10
- 235000010378 sodium ascorbate Nutrition 0.000 claims description 10
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims description 10
- 229960005055 sodium ascorbate Drugs 0.000 claims description 10
- 239000001488 sodium phosphate Substances 0.000 claims description 10
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 10
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims description 10
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 10
- 239000000811 xylitol Substances 0.000 claims description 10
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 10
- 229960002675 xylitol Drugs 0.000 claims description 10
- 235000010447 xylitol Nutrition 0.000 claims description 10
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 claims description 8
- 235000013923 monosodium glutamate Nutrition 0.000 claims description 8
- 229940073490 sodium glutamate Drugs 0.000 claims description 8
- 241000218492 Lactobacillus crispatus Species 0.000 claims description 7
- 241000186606 Lactobacillus gasseri Species 0.000 claims description 7
- 230000002159 abnormal effect Effects 0.000 claims description 6
- 230000003115 biocidal effect Effects 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 244000005706 microflora Species 0.000 claims description 6
- 229920002774 Maltodextrin Polymers 0.000 claims description 5
- 239000005913 Maltodextrin Substances 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 229940088710 antibiotic agent Drugs 0.000 claims description 5
- 229940035034 maltodextrin Drugs 0.000 claims description 5
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 229960000282 metronidazole Drugs 0.000 claims description 4
- 239000007900 aqueous suspension Substances 0.000 claims description 3
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 claims description 2
- 229960002227 clindamycin Drugs 0.000 claims description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 2
- 229960005053 tinidazole Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 6
- 241001561398 Lactobacillus jensenii Species 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000008176 lyophilized powder Substances 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 241000186783 Lactobacillus vaginalis Species 0.000 description 2
- 229940063189 metrogel Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762529756P | 2017-07-07 | 2017-07-07 | |
| US62/529,756 | 2017-07-07 | ||
| PCT/US2018/040884 WO2019010282A1 (en) | 2017-07-07 | 2018-07-05 | STABILIZED FORMULATIONS WITH HIGH POWER OF LACTOBACILLUS VAGINAL |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020526583A JP2020526583A (ja) | 2020-08-31 |
| JP2020526583A5 true JP2020526583A5 (enExample) | 2021-08-12 |
| JP7347760B2 JP7347760B2 (ja) | 2023-09-20 |
Family
ID=64950361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521496A Active JP7347760B2 (ja) | 2017-07-07 | 2018-07-05 | 高効力かつ安定な膣ラクトバチルス調製物 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20200171107A1 (enExample) |
| EP (1) | EP3648778A4 (enExample) |
| JP (1) | JP7347760B2 (enExample) |
| CN (1) | CN110869036B (enExample) |
| AU (1) | AU2018298117B2 (enExample) |
| CA (1) | CA3068958A1 (enExample) |
| WO (1) | WO2019010282A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3648778A4 (en) * | 2017-07-07 | 2021-05-05 | Osel, Inc. | HIGHLY EFFECTIVE STABLE FORMULATIONS OF VAGINAL LACTOBACILLUS |
| US11278581B2 (en) * | 2017-07-07 | 2022-03-22 | Osel, Inc. | Use of vaginal Lactobacilli for improving the success rate of in vitro fertilization |
| TWI737210B (zh) * | 2020-03-06 | 2021-08-21 | 財團法人食品工業發展研究所 | 菌酛保護劑配方及其用途 |
| CN113755357A (zh) * | 2020-06-04 | 2021-12-07 | 内蒙古伊利实业集团股份有限公司 | 一种乳杆菌制剂及其用途 |
| WO2022175680A1 (en) | 2021-02-19 | 2022-08-25 | Imperial College Innovations Limited | Lactobacillus crispatus composition for use in pregnant subjects |
| WO2022185121A1 (en) * | 2021-03-03 | 2022-09-09 | Freya Biosciences Aps | Vaginal microbiota-associated methods, compositions, and devices |
| US12185767B2 (en) * | 2021-11-05 | 2025-01-07 | Trillium Medical Products, LLC | Infused undergarment |
| WO2025016986A1 (en) * | 2023-07-14 | 2025-01-23 | Dsm Ip Assets B.V. | Lactic acid bacteria composition |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2463768A (en) * | 1945-09-05 | 1949-03-08 | Phillips Petroleum Co | Alkylation process |
| US3897307A (en) * | 1974-10-23 | 1975-07-29 | Hansens Lab Inc | Stabilized dry cultures of lactic acid-producing bacteria |
| US6093941A (en) | 1993-09-09 | 2000-07-25 | The United States Of America As Represented By The Secretary Of The Navy | Photonic silicon on a transparent substrate |
| ES2167719T3 (es) * | 1996-09-10 | 2002-05-16 | Nestle Sa | Alimento deshidratado que contiene bacterias de acido lactico. |
| US6093394A (en) * | 1997-04-11 | 2000-07-25 | Gynelogix, Inc. | Vaginal lactobacillus medicant |
| SE521022C2 (sv) * | 2001-09-20 | 2003-09-23 | Ellen Ab | Mjölksyraproducerande bakterier för användning som probiotiska organismer i vaginan hos människa |
| US20110066137A1 (en) * | 2007-12-18 | 2011-03-17 | Osel, Inc. | Applicator for applying powder formulations and uses thereof |
| US8642029B2 (en) | 2008-03-31 | 2014-02-04 | Osel, Inc. | Transiently buffered Lactobacillus preparations and use thereof |
| US8329447B2 (en) * | 2008-12-12 | 2012-12-11 | Osel, Inc. | Strain of Lactobacillus crispatus |
| KR101821417B1 (ko) * | 2009-04-30 | 2018-01-23 | 인트랙슨 액토바이오틱스 엔.브이. | 유산균의 냉동건조에 사용하기 위한 냉동보호제 |
| PH12013500272B1 (en) * | 2010-08-13 | 2019-07-03 | Advanced Bionutrition Corp | Dry storage stabilizing composition for biological materials |
| FR2992973B1 (fr) * | 2012-07-09 | 2015-12-18 | S P M D | Nouvelle souche de lactobacillus crispatus |
| CN102757922B (zh) | 2012-07-30 | 2013-11-20 | 陕西省科学院酶工程研究所 | 嗜酸乳杆菌复合冻干保护剂及其制备和使用方法 |
| US8906668B2 (en) * | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| WO2014106541A1 (en) * | 2013-01-04 | 2014-07-10 | Ellen Ab | Dermal composition for use in the external genital area in females |
| JP6890419B2 (ja) * | 2013-11-08 | 2021-06-18 | スーヂョウ オーセル バイオ−ファーム カンパニー、リミテッド | ラクトバチルス・クリスパタスおよびその応用 |
| CN104178437B (zh) * | 2013-11-08 | 2016-08-24 | 苏州欧赛微科生物医药科技有限公司 | 一种卷曲乳杆菌及其在妇科疾病中的应用 |
| CN108271382A (zh) | 2015-10-30 | 2018-07-10 | 株式会社益力多本社 | 微生物干燥菌体的制造方法 |
| EP3648778A4 (en) * | 2017-07-07 | 2021-05-05 | Osel, Inc. | HIGHLY EFFECTIVE STABLE FORMULATIONS OF VAGINAL LACTOBACILLUS |
-
2018
- 2018-07-05 EP EP18827562.2A patent/EP3648778A4/en active Pending
- 2018-07-05 AU AU2018298117A patent/AU2018298117B2/en active Active
- 2018-07-05 CA CA3068958A patent/CA3068958A1/en active Pending
- 2018-07-05 JP JP2020521496A patent/JP7347760B2/ja active Active
- 2018-07-05 US US16/627,118 patent/US20200171107A1/en not_active Abandoned
- 2018-07-05 WO PCT/US2018/040884 patent/WO2019010282A1/en not_active Ceased
- 2018-07-05 CN CN201880045148.3A patent/CN110869036B/zh active Active
-
2020
- 2020-03-20 US US16/825,225 patent/US11083761B2/en active Active
-
2021
- 2021-07-09 US US17/372,325 patent/US12303538B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020526583A5 (enExample) | ||
| US4314995A (en) | Pharmaceutical lactobacillus preparations | |
| US7759105B2 (en) | Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions | |
| EP0923293B1 (en) | Treatment of diarrhea | |
| US7731976B2 (en) | Treatment of irritable bowel syndrome using probiotic composition | |
| US7749509B2 (en) | Treatment of autism using probiotic composition | |
| EP3139939B1 (en) | Compositions and methods for treating skin and mucous membrane diseases | |
| US8853269B2 (en) | Composition and method for treating infections and promoting intestinal health | |
| ES2426258T3 (es) | Composiciones farmacéuticas que comprenden bacterias que reducen oxalato | |
| US20100303782A1 (en) | Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions | |
| MXPA97009318A (en) | Lactobacilos micro-encapsulados para aplicacionesmedi | |
| JP2017025078A (ja) | 膣症を予防および治療するために塩および糖を有効成分として含む皮膚外用組成物およびその使用 | |
| EP3651783A1 (en) | New probiotic composition for prevention of bacterial vaginosis | |
| CN106860451A (zh) | 一种利福霉素‑硝基咪唑偶联分子的新应用 | |
| WO2022090254A1 (en) | Direct delivery of vitamins to inhibit microbial pathogens | |
| JP2005507670A (ja) | プロバイオティック組成物 | |
| CN101411714A (zh) | 治疗阴道炎的化学物质 | |
| JPH02503800A (ja) | 炎症過程及びアレルギー性疾患の予防及び治療のための細菌性製剤 | |
| AU2018212530B2 (en) | Fecal microbiota for treating patients undergoing a hematopoietic stem cell transplant | |
| JP2012514629A (ja) | 経口送達のための生細胞の配合物 | |
| Dressler et al. | Ambulation of Patients with Pulmonary Tuberculosis Under Protection of Chemotherapy, A Preliminary Report | |
| CA2383626A1 (en) | Treatment of dermal tumors, warts, and viral infections using heat-killed p. acnes | |
| CN101766603A (zh) | 一种增强免疫力的肌肉注射给药的注射液 | |
| Hyman | Anaphylactic shock after therapy with penicillinase | |
| NZ569627A (en) | The use of virginiamycin for preventing reduced feed intake and treating laminitis, fermentative acidosis, equine grass sickness and pulpy kidney |